The company has advanced CTP-656 nicely since receiving U.S. patent in the fall of 2014. Below is a chronology of the drug's clinical progress.
First Half 2017 - European switching study CTP-656, and Kalydeco.
✔ January 2017 - Start phase 2 for mono-therapy, various gating mutations.
✔ February 2016 - Food effect study in healthy male volunteers, solid oral dose.
✔ November 2015 - Multiple ascending dose (PK) crossover study, with CTP-656 and Kalydeco in healthy volunteers, solid oral dose.
✔ March 2015 - Single ascending dose (PK) crossover study, with CTP-656, and Kalydeco in healthy volunteers, oral suspension. Second part of phase 1.
✔ March 2015 - Phase 1, D9 and D18 analog (PK) comparison in healthy volunteers. The first part of phase 1.
✔ 2012 - Pre-clinical D9, D18 and Kalydeco plasma study comparison in dogs.
Thank you for reading.
First Half 2017 - European switching study CTP-656, and Kalydeco.
✔ January 2017 - Start phase 2 for mono-therapy, various gating mutations.
✔ February 2016 - Food effect study in healthy male volunteers, solid oral dose.
✔ November 2015 - Multiple ascending dose (PK) crossover study, with CTP-656 and Kalydeco in healthy volunteers, solid oral dose.
✔ March 2015 - Single ascending dose (PK) crossover study, with CTP-656, and Kalydeco in healthy volunteers, oral suspension. Second part of phase 1.
✔ March 2015 - Phase 1, D9 and D18 analog (PK) comparison in healthy volunteers. The first part of phase 1.
✔ 2012 - Pre-clinical D9, D18 and Kalydeco plasma study comparison in dogs.
Thank you for reading.
No comments:
Post a Comment